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It has been suggested that progenitor cell–based therapy us-ing autologous bone marrow might represent a source to 
improve left ventricular (LV) function in patients with acute 
myocardial infarction (AMI), when administered after success-
ful percutaneous coronary intervention (PCI). Meta-analyses 
using publication-based data sets of the so far published ran-
domized controlled clinical trials revealed mostly modest, but 
significant benefits on LV remodeling.1–6 The largest benefit 
has attributed to patients of younger age and with a severely 
impaired LV ejection fraction (LVEF).1 Most recently, the only 
meta-analysis using individual patient data7 challenged these 
earlier results by showing no improvement of LVEF, ventricular 
remodeling, or clinical events with autologous bone marrow–
derived mononuclear cells (BM-MNC). The individual results 
of the trials, which were included in that meta-analysis, were 
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Rationale: Intracoronary delivery of autologous bone marrow–derived mononuclear cells (BM-MNC) may improve 
remodeling of the left ventricle (LV) after acute myocardial infarction (AMI).
Objective : To demonstrate long-term efficacy of BM-MNC treatment after AMI.
Methods and Results : In a multicenter study, we randomized 200 patients with large AMI in a 1:1:1 pattern into 
an open-labeled control and 2 BM-MNC treatment groups. In the BM-MNC groups, cells were either administered 
5 to 7 days (early) or 3 to 4 weeks (late) after AMI. Cardiac magnetic resonance imaging was performed at baseline 
and after 12 months. The current analysis investigates the change from baseline to 12 months in global LV ejection 
fraction, LV volumes, scar size, and N-terminal pro-brain natriuretic peptide values comparing the 2 treatment 
groups with control in a linear regression model. Besides the complete case analysis, multiple imputation analysis 
was performed to address for missing data. Furthermore, the long-term clinical event rate was computed. The 
absolute change in LV ejection fraction from baseline to 12 months was −1.9±9.8% for control (mean±SD), 
−0.9±10.5% for the early treatment group, and −0.7±10.1% for the late treatment group. The difference between 
the groups was not significant, both for complete case analysis and multiple imputation analysis. A combined 
clinical end point occurred equally in all the groups. Overall, 1-year mortality was low (2.25%).
Conclusions : Among patients with AMI and LV dysfunction, treatment with BM-MNC either 5 to 7 days or 3 to 
4 weeks after AMI did not improve LV function at 12 months, compared with control. The results are limited by 
an important drop out rate.
Clinical Trial Registration Information: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00355186.  
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heterogeneous with respect to surrogate end points, such as 
LVEF or changes in LV volume. Moreover, their key outcomes 
had been mainly analyzed within a rather short follow-up pe-
riod of 4 to 6 months after administration of BM-MNC.8–17
The SWISS-AMI study18 assessed whether early (5–7 days) 
or late (3–4 weeks) intracoronary delivery of BM-MNC will af-
fect the recovery of LV function after AMI. At 4 months follow-
up, no significant change in LVEF in the treatment groups when 
compared with control was seen.13 However, less is known about 
the long-term effects of BM-MNC therapy on LV remodeling. 
In the Repair-AMI trial, Assmus et al19,20 reported a significant 
reduction of adverse clinical events and a sustained improve-
ment of LV function after BM-MNC treatment at 2 and 5 years, 
respectively. Likewise, in line with an earlier meta-analysis,4 
the initially observed improvement in LVEF was maintained ≤5 
years of follow-up in an early pilot study of our own group.21 
In contrast, in a randomized trial by Meyer et al,22 LV function 
as assessed by cardiac magnetic resonance imaging (CMR) de-
creased by about 3 absolute points in both the control and BM-
MNC–treated groups at 5 years.22 Most recently, Traverse et al23 
reported the 1-year CMR results of the Timing in Myocardial 
Infarction Evaluation (TIME) trial and confirmed their earlier 
neutral results of BM-MNC therapy. Here, we report the com-
pleted 1-year CMR and biohumoral results of the SWISS-AMI 
trial and the available clinical event rates ≤5 years of follow-up.
Methods
Study Sample and Protocol
The entire study design with predefined inclusion and exclusion cri-
teria have been previously described.13,18 In brief, patients with acute 
ST-segment–elevation myocardial infarction (STEMI) and successful 
PCI within 24 hours after symptom onset were eligible for enroll-
ment into this multicenter, randomized, controlled trial (RCT) pro-
vided they presented with an LVEF of <45% as assessed by an LV 
angiogram or transthoracic echocardiography the day of or after the 
AMI. After giving their informed consent to participate to the study, 
patients were randomly assigned in a 1:1:1 fashion to 1 open-labeled 
control and 2 BM-MNC treatment groups. The control group re-
ceived best medical management according to current guidelines,24 
including aspirin and clopidogrel or prasugrel, statins, β-blockers, 
and ACE-inhibitors or ATII-receptor blockers, as well as aldosterone 
antagonists, if indicated. The early treatment group received intracor-
onary BM-MNC infusion 5 to 7 days and the late treatment group 3 
to 4 weeks after primary PCI, on top of the best medical management. 
LV function was assessed by CMR in all patients at baseline, at 4 
and 12 months after AMI. The hypothesis was that both the treatment 
groups had equal efficacy to raise LVEF when compared with con-
trol patients. A total of 4 Swiss tertiary centers (University Hospital, 
Zurich; Bern University Hospital; Cantonal Hospital; and Lucerne 
and Fondazione Cardiocentro Ticino) participated in this trial. The 
study was conducted in accordance with the declaration of Helsinki, 
and the protocol was approved by the regional ethical Committee of 
each participating center and by the Federal competent authorities 
(Swissmedic and Federal Office of Public Health).
Bone Marrow Aspiration, Cell Processing, and 
Intracoronary Infusion
All procedures have been precisely described elsewhere.13,18 In brief, 
bone marrow samples were collected under sterile conditions from the 
iliac crest in local anesthesia. The cell processing was entirely per-
formed in a centralized, good manufacturing practice–certified facility 
(Cell Therapy Unit, Cardiocentro Ticino, Lugano, CH, Switzerland) 
by using density gradient centrifugation. The mononuclear cell frac-
tion was then resuspended in 10 mL of serum-free medium added with 
20% of autologous serum without adding any heparin.
Cell viability, functional testing, characterization of the product, 
and sterility were assessed from an aliquot of the cell suspension. 
BM-MNC were then administered in the former infarct-related vessel 
by performing the previously described stop-flow technique.13,18
CMR Imaging
As previously described, cardiac imaging was performed using 
1.5-Tesla clinical magnetic resonance systems with dedicated car-
diac phased–array receiver coils for signal reception. All patients 
underwent CMR studies during the hospitalization for the AMI 
(baseline). The studies were then repeated after 4 and 12 months. 
Functional imaging of the LV was performed by means of standard 
ECG-triggered steady state–free precession acquisitions during re-
petitive breath holds in 3 long-axis orientations and in contiguous 
short-axis orientation, covering the entire LV. A bolus of a conven-
tional extracellular gadolinium-chelates contrast medium at a dose 
of 0.20 mmol/kg of body weight was administered to assess myo-
cardial scar imaging, by using an inversion recovery fast gradient 
echo imaging sequence.25–28 Scar imaging was performed 20 min-
utes after administration of contrast medium in identical locations 
as functional data were acquired.
CMR data analysis was performed in a core laboratory (University 
Hospital Zurich/CH, Switzerland) using dedicated cardiac analysis 
software (GTVolume, Gyrotools Ltd, Zurich/CH). LV end-diastolic 
(LVEDV) and end-systolic (LVESV) volumes, LVEF, and LV mass 
have been quantified for the assessment of the change of LVEF and 
for the assessment of ventricular remodeling over time in the 3 study 
groups. Scar mass was assessed in grams (g).
Clinical Follow-Up
Adverse clinical events, Canadian Cardiac Society (CCS), and New 
York Heart Association (NYHA) class were assessed at 4 and 12 
months after AMI performing dedicated follow-up visits, which were 
scheduled together with the CMR data acquisition. Thereafter, sys-
tematic annual telephone visits were performed ≤5 years after AMI. 
During these visits, clinical events were systematically asked directly 
to the patient by trained medical study investigators. Patients were 
classified as alive only if a direct contact could have been established.
N-Terminal Pro-Brain Natriuretic Peptide
As per protocol, N-terminal pro-brain natriuretic peptide (NT-
proBNP) values were supposed to be assessed for the entire study 
population at baseline, during 4 and 12 months follow-up, and the 
analysis was performed in a central laboratory (Department of 
Clinical Chemistry, University Hospital, Zurich, Switzerland).
End Points
The following end points are presented: change in LV function and re-
modeling at 12 months follow-up (LVEF, LVEDV, LVESV, and infarct 
size) as well as the change of NT-proBNP over the entire follow-up. 
We also report on the mid- to long-term clinical follow-up and events 
Nonstandard Abbreviations and Acronyms
AMI acute myocardial infarction
BM-MNC autologous bone marrow–derived mononuclear cells
CMR cardiac magnetic resonance imaging
LVEDV left ventricular end-diastolic volume
LVESV LV end-systolic volume
NT-proBNP N-terminal pro-brain natriuretic peptide
NYHA New York Heart Association
PCI percutaneous coronary intervention
RCT randomized controlled trial
STEMI ST-segment–elevation myocardial infarction
TIME Timing in Myocardial Infarction Evaluation
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(survival and major adverse event–free survival ≤5 years). The fol-
lowing major adverse events are included in the combined end point: 
all-cause death, recurrence of myocardial infarction, any coronary re-
vascularization procedure, stroke, or rehospitalization for heart failure.
Statistical Analysis
Baseline Characteristics
Continuous data are described either as mean and SD or as median 
and 25th to 75th percentiles, whenever more appropriate. Categorical 
data are expressed as counts and percent. Comparison between treat-
ment arms at baseline is performed with the Kruskal–Wallis test and 
the Fisher exact test, respectively. Adherence to state-of-the-art phar-
macological treatment after STEMI and depressed LV function was 
assessed at baseline and after 4 and 12 months. Only descriptive sta-
tistics of the difference between groups are shown.
Evaluation of Follow-Up Data Through 1 Year
To assess whether profiles over time are different between the 3 treat-
ment arms, comparisons of the changes over time (ie, between baseline, 
4 months, and 12 months) of the above-described end points (includ-
ing NT-proBNP values) between the 3 treatment groups have been per-
formed. To do so, a multivariable linear regression model for repeated 
measures has been fitted, including the factors treatment and time as well 
as their interaction. Huber White robust SEs were computed to account 
for intrapatient correlation of measures over time. Given that 5 different 
end points are assessed, interaction is considered statistically significant 
when the P value is <0.01 (Bonferroni correction). For all other explor-
atory (unadjusted) post hoc comparisons, P values are to be considered 
descriptive only. In all models, treatment effect was adjusted for age, sex, 
history of coronary artery disease, diabetes mellitus, and baseline LVEF. 
Residuals were graphically inspected to assess model fit.
Median follow-up was described using the inverse Kaplan–Meier 
method. Cumulative (event-free) survival was plotted using the 
Kaplan–Meier method and compared with the log-rank test. Time 
to the first event was considered. The primary comparisons were 
performed between control and the 2 treatments arms (early and 
late). Further comparisons of control and 1 combined treatment arm 
(early+late) are shown in the Online Data Supplement.
Adjustment for Missing Data
The drop out rate, especially for the CMR protocol and within 
the late therapy group, was high. To account for missing data, we 
therefore performed multiple imputation analysis using chained 
equation,29 which fills in missing values in multiple variables itera-
tively. Fifty data sets were generated after setting a seed for repro-
ducibility. The largest fraction of missing information was used to 
confirm that the number of imputed data sets was adequate (thumb 
rule M=100×fraction of missing information). We imputed the LVEF, 
LVEDV, LVESV, scar size, NT-proBNP, and their changes through 
1 year. We used the following independent variables for imputation: 
age, body mass index, sex, hypertension, dislipidemia, diabetes mel-
litus, smoking (active/previous), family history of coronary artery 
disease, 1-, 2-, or 3-vessel disease, treatment arm, time from pain to 
revascularization, TIMI flow before PCI, TIMI flow after PCI, use 
of glycoprotein IIb/IIIa inhibitors, maximal creatinine kinase values, 
heart failure at baseline, and ventricular fibrillation at presentation. 
The imputed data were then described with the mean and SE or the 
median and SE obtained via quantile regression. The same regression 
models as in the complete case analysis were fitted (while accounting 
for imputation). Details and discussion of the reasons for missingness 
are given in the Online Data Supplement.
All tests were 2 sided. The analysis followed the intention-to-treat 
principle. Stata 14 and Stata 14 mi suite (StataCorp, College Station, 
TX) were used for computation.
Results
A total of 200 patients were enrolled in the study by 4 cen-
ters from October 2006 to January 2012. Sixty-six of them 
were randomized in the early BM-MNC treatment group and 
67 each in the control and late treatment groups, respectively. 
Complete paired CMR analysis (both at baseline and at 12 
months) was available for 150 patients (75%). Twenty-eight 
patients were lost for follow-up because of death (n=4), im-
plantable cardioverter–defibrillator implantation between 
4 and 12 months (n=5), from the CMR protocol because 
Figure 1. Flow diagram of patient enrollment 
until 12-mo follow-up. CMR indicates cardiac 
magnetic resonance imaging; ICD, implantable 
cardioverter–defibrillator; PIC, patient informed 
consent; and STEMI, ST-segment–elevation 
myocardial infarction.
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of patient’s preference (n=7), and because of technical rea-
sons (n=12). For 178 patients (89%), clinical follow-up was 
available at 12 months (22 patients withdrew their informed 
consent to participate in the study). NT-proBNP values were 
assessed in 175 patients at baseline, in 169 patients at 4 months 
of follow-up, and in 163 patients at 12 months of follow-up. 
Complete patient flow from randomization to 12 months of 
follow-up is shown in Figure 1.
Baseline Characteristics
The patient’s baseline characteristics have been previously 
published13 and are shown in Online Table I. Briefly, patients 
in the late treatment group were older, were less frequently 
smokers, and had a higher rate of bivalirudin use during pri-
mary PCI. Furthermore, a trend toward a higher baseline 
LVEF in the control group was observed, which could never 
be entirely explained. Apart from this, there was no statisti-
cally significant difference in baseline characteristics between 
the 3 groups.
Most of the patients (92.3%) had anterior STEMI because 
of occlusion of the left anterior descending coronary artery, 
and the median time from onset of chest pain to reperfusion 
therapy was 4.5 hours (range: 2.75–8 hours). Antithrombotic 
treatment during PCI consisted of 65% of glycoprotein IIb/
IIIa inhibitors and 11% of bivalirudin. The median of maximal 
creatine kinase plasma levels was 3919 U/L (range: 2203–
5867), and baseline LVEF, as assessed by CMR at a median of 
6 (range: 4–8) days after the index STEMI, was 37.4% (range: 
30.9–44.1).
Pharmacological treatment (Table 1) was initiated ac-
cording to current guidelines24 shortly after primary PCI. 
Compliance to prescribed treatment was overall between 90% 
and 100% for dual-antiplatelet therapy, statins, β-blockers, 
ACE-inhibitors, or ATII-receptor blockers, respectively.
The characteristics of the infused BM-MNC have been de-
scribed previously13 and are shown in Online Table II. Briefly, 
a median of 153×106 nucleated cells have been infused in the 
infarct-related artery at a median of 6 days (range: 5–7) af-
ter STEMI in the early and after a median of 24 days (range: 
21–28) after the event in the late treatment group.
Evaluation of Follow-Up Data Through 1 Year
The change in mean LVEF over time within the differ-
ent groups is shown in Table 2 (Complete Case Analysis); 
Figure 2 and the absolute change from baseline to 12 months 
is shown in Figure 3. Specifically, in exploratory comparisons, 
for both the therapy groups, between baseline and 4 months 
follow-up, a nonsignificant trend toward an increase in LVEF 
with a subsequent decrease between 4 and 12 months was ob-
served. In the control group, a constant, but nonsignificant, 
decrease in LVEF was noticed. The absolute within-group 
differences from baseline to 12 months were −1.9 (95% con-
fidence interval, −4.5 to −0.8) for control, −0.9 (−3.8 to 2.0) 
for the early, and −0.7 (−3.9 to 2.4) for the late therapy groups 
(Table 2 [Complete Case Analysis]).
Between baseline and 4 months, negative remodeling 
of the LV occurred predominantly in the control and early 
treatment groups, whereas the late therapy group showed 
a nonsignificant increase of both LVEDV and LVESV 
(Table 2 [Complete Case Analysis]). In all patient groups, 
LV volumes did not further increase from 4 to 12 months, 
indicating that the remodeling process had been mainly con-
cluded at 4 months. The absolute within-group differences 
from baseline to 12 months for LVEDV and LVESV were 
19 mL (range: 5–33) and 17 mL (range: 6–29) for the con-
trol group, 26 mL (range: 13–38) and 21 mL (range: 10–32) 
for the early treatment group, and 11 mL (range: −1 to 23) 
and 10 mL (range: −0 to 21) for the late therapy group, re-
spectively. As expected, in all groups, total scar mass uni-
formly and significantly decreased between baseline and 
12 months without any difference between groups (Table 2 
[Complete Case Analysis]). At multivariable repeated mea-
sures analysis, none of LVEF, LVEDV, LVESV, and scar 
size showed differences over time between control and the 
2 treatment arms, as documented by the nonsignificant in-
teractions (Table 2 [Complete Case Analysi)]; Online Table 
III for model details).
Additional comparisons between control and the com-
bined treatment arm (early+late) are shown in the Online Data 
Supplement (Online Figure I). The results were not different 
from the initial comparisons between the 3 distinct groups.
As expected, NT-proBNP values were highest at the time 
of the event and then decreased significantly in all the 3 groups 
≤4 months of follow-up. In terms of absolute change between 
baseline and 12 months of follow-up, there was a trend to-
ward a more pronounced improvement of NT-proBNP values 
in favor of both the therapy groups (Figure 3). However, with 
multivariable repeated-measures analysis, no difference was 
seen any longer between the 3 groups (nonsignificant interac-
tions in Table 2 [Complete Case Analysis]; Online Table IIIA 
for model details).
Table 1. Descriptive Statistic of the Pharmacological Treatment of the Included Patients at Baseline, 
After 4 and 12 Months
Control (n=67) Early (n=65) Late (n=63)
Aspirin 98.5/98.4/95.7 98.4/98.4/95.7 98.3/98.2/97.4
P2Y12 antagonist 100/100/93.5 100/100/86.7 100/98.2/92.3
ACE-inhibitor or ATII-receptor blocker 95.5/100/100 100/100/93.5 96.6/98.2/97.5
β-Blocker 86.4/85.2/87.0 91.9/88.5/84.8 93.2/92.6/89.7
Aldosterone antagonist 12.1/11.5/8.7 12.9/14.8/10.9 15.2/9.3/15.4
Statin 97.0/98.4/95.7 100/95.1/93.5 98.3/100/100
Medication at discharge/after 4/and 12 months, %. ACE indicates angiotensin-converting enzyme; and AT, angiotensin.
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Adjustment for Missing Data
The results of the comparisons of the different treatment 
groups after multiple imputation to account for missing data 
are shown in Table 2 [Multiple Imputation]. They seemed 
similar to the complete case analysis, both in the data descrip-
tion and the comparison of time profile, as can be easily iden-
tified by direct comparison with the results of the complete 
case analysis (Table 2 [Complete Case Analysis and Multiple 
Imputation]). Details of the regression models are reported in 
the Online Table IIIA and IIIB.
Clinical Follow-Up and Events
At 12 months, 84% of the patients were in NYHA class I and 
98% of them were free of any angina (without any difference 
between groups). As shown in Table 3, the clinical event rate 
at 12 months was similar within the 3 groups for any of the 
Table 2. Comparison of Changes Over Time in the 3 Study Arms
Complete Case Analysis Multiple Imputation
Control 
(n=55) Early (n=53) Late (n=42)
P Value for 
Interaction* Control (n=55) Early (n=53) Late (n=42)
P Value for 
Interaction*
LVEF, %
  Baseline 40.0 (9.9) 36.5 (9.9) 36.3 (8.2) 0.640 39.9 (1.3) 35.7 (1.3) 36.3 (1.1) 0.688
  4 mo 39.6 (12.0) 37.9 (10.3) 37.4 (9.7) 39.6 (1.5) 37.2 (1.4) 37.0 (1.4)
  12 mo 38.1 (13.6) 36.2 (11.4) 36.6 (12.2) 38.6 (1.7) 35.2 (1.5) 36.7 (1.7)
Δ bl–12 mo −1.9  
(−4.5 to −0.8)
−0.9  
(−3.8 to 2.0)
−0.7  
(−3.9 to 2.4)
−1.8  
(−4.4 to 0.7)
−0.9  
(−3.7 to 1.9)
−0.6  
(−3.4 to 2.2)
LVEDV, mL
  Baseline 153 (38) 156 (41) 157 (37) 0.063 153 (5) 158 (6) 157 (5) 0.292
  4 mo 180 (52) 183 (55) 167 (45) 178 (7) 182 (7) 167 (7)
  12 mo 170 (56) 179 (61) 164 (47) 170 (7) 178 (8) 163 (7)
Δ bl–12 mo 19 (5 to 33) 26 (13 to 38) 11 (−1 to 23) 20.5  
(6.6 to 34.3)
26.0  
(14.0 to 38.1)
10.3  
(−2.0 to 22.6)
LVESV, mL
  Baseline 94 (33) 100 (36) 100 (29) 0.199 94 (4) 103 (5) 100 (4) 0.490
  4 mo 112 (46) 117 (51) 107 (40) 111 (6) 117 (7) 107 (6)
  12 mo 110 (53) 118 (56) 107 (44) 109 (7) 119 (7) 107 (7)
Δ bl–12 mo 17 (6 to 29) 21 (10 to 32) 10 (−0 to 21) 18.6  
(6.8 to 30.3)
22.0  
(11.4 to 32.5)
10.0  
(−0.4 to 20.5)
Scar size, g
  Baseline 45.3 (28.0) 44.0 (22.3) 38.5 (22.5) 0.181 44.0 (3.4) 45.4 (3.0) 38.0 (3.0) 0.702
  4 mo 29.2 (15.7) 28.9 (15.7) 24.3 (11.1) 29.2 (2.2) 30.3 (2.2) 25.5 (2.2)
  12 mo 22.0 (12.2) 24.1 (13.1) 22.4 (13.1) 23.1 (2.2) 26.5 (2.2) 23.3 (2.5)
Δ bl–12 mo −23  
(−29 to −16)
−22  
(−28 to −17)
−16  
(−24 to −8)
−21.4  
(−27.9 to −14.9)
−23.5  
(−29.5 to −17.6)
−16.6  
(−23.7 to −9.4)
NT-proBNP, pg/mL‡
  Baseline 1103  
(737–2580)
1450  
(901–2355)
1581  
(937–2889)
0.404 1139 (227) 1508 (197) 1539 (244) 0.736
  4 mo 416  
(206–842)
501  
(240–912)
467  
(284–949)
440 (90) 534 (101) 557 (135)
  12 mo 332  
(110–672)
291  
(172–566)
330  
(122–591)
360 (84) 310 (60) 362 (86)
Δ bl–12 mo −1012  
(−1376 to −65)
−1624  
(−2145 to −1103)
−1488  
(−1828 to −1147)
−1048  
(−1442 to −654)
−1681  
(−2187 to −1175)
−1538  
(−1936 to −1139)
Complete Case Analysis: All values are given as mean (SD) or ‡median (25th–75th percentiles). Δ bl-12 months is change from baseline to 12 months and is given 
as mean (95% confidence interval). The number of the subjects in each population can be found in Figure 2. Multiple Imputation: All values are given as mean (SE) of 
the imputed variables or ‡median (SE). Δ bl-12 months is change from baseline to 12 months and is given as mean (95% confidence interval). The model has been 
fitted accounting for the imputation process. The model is adjusted for age, sex, history of coronary artery disease, diabetes mellitus, and baseline LVEF. The test 
for interaction tests whether the profile over time of the measured variables is different between treatment arms. P value for significance is set at 0.01 (Bonferroni 
correction). Details of the regression models results are given in the Online Table III. Bl indicates baseline; LVEDV, left ventricular end-diastolic volume; LVEF, LV ejection 
fraction; LVESV, LV end-systolic volume; and NT-proBNP, N-terminal pro-brain natriuretic peptide.
*P value for interaction: derives from a general linear model for repeated measures, including both the main effects for treatment and time and their interaction.
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assessed events or their combination. Events occurring be-
tween randomization and cell therapy and during the cumula-
tive 12 months thereafter are presented separately.
Clinical events were furthermore followed ≤5 years (me-
dian follow-up: 38 months). As shown in Figure 4, mortality 
remained low, that is, 2.25% at 12 months and 2.3% at 24 
months, in all the 3 groups ≤5 years after the event without 
between-group differences (log-rank test P=0.43), regardless 
of the fact that high-risk patients with large STEMIs were 
enrolled. No death occurred in the control group, whereas 3 
patients (5.8%) died in the early and 1 patient (2.3%) died 
in the late treatment groups. Of note, however, 2 deaths (1 in 
each treatment group) occurred between randomization and 
the scheduled BM-MNC treatment. Also, the major adverse 
event–free survival was comparable between the 3 groups 
(Figure 4, log-rank test P=0.65) for the combined end point of 
all-cause death, recurrent myocardial infarction, any coronary 
revascularization, and stroke or rehospitalization for heart 
failure.
Discussion
The Swiss-AMI trial is the largest RCT, which aimed to 
address LV function by CMR not only at 4 months after 
STEMI but also at 12 months of follow-up. Furthermore, 
together with the TIME trial,16,23 it is the only RCT, which 
addressed 2 time points, either an early or a late time points 
after BM-MNC administration. Both the treatment groups 
were compared with a control arm in a unique trial design, 
assuming an equal treatment effect. Similar to what we re-
ported at short term,13 we were also unable to demonstrate 
a significant treatment effect of BM-MNC 12 months after 
the initial event in both the treatment groups. Although at 
4 months a small increase in LVEF was observed in both 
the treatment groups, there was a nonsignificant decrease 
in LVEF from baseline to 12 months for all groups without 
any within-group difference. In particular, between 4 and 12 
months, a trend toward a decrease in LVEF was apparent in 
all the 3 groups. Negative remodeling was not notable in the 
late treatment group, but was notable in the early treatment 
and control groups. The latter finding, however, is difficult to 
interpret because it was not associated with an improvement 
in LV function. Although the CMR protocol of the Swiss-
AMI trial had a relatively high drop out rate, the robustness 
of the results was confirmed by the fact that multiple impu-
tation analyses to address for missing data only marginally 
changed the outcomes of the study.
More than a decade after the publication of the  first RCTs, 
the results of our study underscore that it is still unclear if BM-
MNC, administered within the first weeks after STEMI, exert a 
beneficial effect on LV function during follow-up. The results 
Figure 2. Descriptive statistic of the mean left ventricular ejection fraction (LVEF, %) values at baseline, after 4 and 12 months for 
control, early and late bone marrow–derived mononuclear cell treatment. LVEDV indicates LV end-diastolic volume; LVESV, LV end-
systolic volume; and NT-proBNP, N-terminal pro-brain natriuretic peptide.
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of earlier RCTs9,12,17 and those of several meta-analyses1,2,5,6 
were mainly suggesting a positive effect of BM-MNC treat-
ment on LV function. Indeed, the earlier studies showed a small 
increase in LVE and a reduction in LV volumes and suggested 
potential clinical benefit. In contrast, more recent studies,13,15,16 
using CMR as a standard to assess LV function, were not able to 
confirm a significant effect of intracoronary BM-MNC admin-
istration in patients with STEMI undergoing successful primary 
PCI. Similarly, a recent meta-analysis, using individual patient 
data of the included trials,7 did not show any effect on LVEF 
and was not able to confirm a positive effect on LV remodel-
ing either. As a consequence, there is an ongoing debate how 
such discrepancies may be explained. Most of the meta-anal-
yses were using publication-based data sets such as the num-
ber of patients in the treated and control groups and the mean 
changes from baseline to follow-up including the SD of both 
groups. An advantage of the meta-analysis based on individual 
patient data, such as the Meta-Analysis of Cell-Based Cardiac 
Studies (ACCRUE) consortium,7 is the use of effectively col-
lected data of each participating study and a lower heterogene-
ity between the included trials and the exclusion of withdrawn 
studies (such as the Strauer series) and those without published 
changes in LVEF (often the case in smaller studies). Such an 
approach avoids the necessity to recalculate changes based on 
mathematical formula. However, some trials had to be left out 
from the meta-analysis because of the unwillingness of the au-
thors to provide individual patient data, which somewhat weak-
ens the generalizability of that recent meta-analysis. Thus, also 
meta-analyses of any nature are not able to give the definitive 
answer to the still unresolved issue if the intracoronary injection 
of BM-MNC shortly after STEMI will improve LV function or 
outcome.
The durability of a putative beneficial effect of BM-MNC 
is even less well studied. The mid-term outcome of the Swiss-
AMI trial between 4 and 12 months is partially in line with 
the 5-year results of Meyer et al22 who also described a late 
decrease in LVEF of 3 absolute percentage points in the control 
and treatment groups. Furthermore, there are important simi-
larities between our study and the TIME trial16,23 with regard 
to the study design by addressing 2 different time points of 
cell administration and the use of CMR to assess LV function. 
Likewise, the results of both the trials and the conclusions seem 
Figure 3. Descriptive statistic (columns) of the mean absolute change in left ventricular ejection fraction (LVEF, %), LV end-
diastolic volume (LVEDV, mL), LV end-systolic volume (LVESV, mL), and N-terminal brain natriuretic peptide (pg/mL) from baseline 
to 12 mo for control, early and late bone marrow–derived mononuclear cell treatment.
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strikingly similar, for both the short- and the long-term results. 
As in the TIME trial,23 we also pooled both therapy groups in 
a secondary analysis without any substantial change of results.
The long-term clinical outcome of the Swiss-AMI trial was 
characterized by a surprisingly low overall mortality rate of only 
2.25% at 1 year and of 2.3% at 2 years. Furthermore, no differ-
ence between the 3 groups was observed as for the combined 
clinical end point of death, myocardial infarction, revasculariza-
tion of any kind, or rehospitalization for heart failure. The low 
mortality rate of our study at 1 and 2 years of follow-up leads 
to 2 further conclusions: first, mortality after large STEMIs in 
the era of modern reperfusion therapy with primary PCI present-
ing in a hemodynamically stable condition is much lower than 
generally expected. This could play a crucial role for the ongo-
ing The Effect of Intracoronary Reinfusion of BM-MNC on All 
Cause-Mortality in AMI (BAMI) trial (NCT 01569178), which 
assumed a 12% of mortality rate after 2 years using similar inclu-
sion criteria as the here presented SWISS-AMI trial. Second, as 
for all-cause mortality, also for the combined clinical end point, 
no significant difference could be detected between the control 
and treatment groups ≤38 months. Importantly, our results con-
tradict the positive long-term results of the Repair-AMI study, to 
which our group participated as recruiting center, and the findings 
of several meta-analyses,2,19 which were both showing a potential 
positive effect of BM-MNC treatment on mortality and outcome.
Interestingly, NT-proBNP, a biomarker of LV dysfunction, 
which is closely related to prognosis,30,31 was the only parameter 
pointing to a potential treatment effect of BM-MNC. Only in both 
the BM-MNC therapy groups, a near normalization NT-proBNP 
levels occurred between 4 and 12 months, whereas in the con-
trol group, the values did not further decrease within this time 
period. The difference between groups tended to be significant 
Table 3. Major Adverse Cardiac Events at 12 Months
Control Early Late P Value
Events between randomization and therapy
  Death 0 1 (1.9%) 1(2.3%) 0.24
Events at 12-mo follow-up (cumulative)
  Death 0 3 (5.8%) 1 (2.3%) 0.32
  Myocardial infarction 2 (4.4%) 1 (2.0%) 0 0.25
  Rehospitalization for heart failure 3 (6.5%) 1 (2.0%) 3 (7.1%) 0.50
  Revascularization 6 (12.8%) 4 (7.8%) 4 (9.3%) 0.73
  Cerebral infarction/TIA 2 (4.4%) 2 (4.1%) 0 0.55
  ICD implantation 1 (2.2%) 2 (4.1%) 3 (7.1%) 0.48
Combined events
  Death, myocardial infarction, revascularization, and 
rehospitalization for heart failure
9 (19.3%) 8 (15.6%) 8 (18.6%) 0.88
  Death, myocardial infarction, revascularization, and 
rehospitalization for heart failure or stroke
11 (23.7%) 10 (19.7%) 8 (18.6%) 0.77
ICD indicates implantable cardioverter–defibrillator; and TIA, transient ischemic attack.
Figure 4. Kaplan–Meier curves for the incidence of death or the combined clinical end point of death, myocardial infarction, any 
coronary revascularization, rehospitalization for heart failure or stroke for control (blue curve), and early (red curve) or late bone 
marrow–derived mononuclear cell treatment (green curve).
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only for absolute changes between baseline and 12 months, but 
not in the regression model and after accounting for missing data. 
Obviously, the role of NT-proBNP has never been validated as a 
marker of outcome for cell-based treatment studies, which limits 
the value of these data. Further investigations are, thus, required 
to clarify if NT-proBNP may be a helpful surrogate marker in 
addition to LVEF to assess the clinical use of cell-based therapy.
Study Limitations
The limitations of the SWISS-AMI trial have been extensively 
discussed previously.13 One limitation is the important drop 
out rate. The withdrawal rate from the study protocol was 
higher in the late therapy group, particularly during the first 
3 weeks, that is, during the waiting time between discharge 
from hospital after primary PCI and the planned rehospitaliza-
tion for cell therapy. Likewise, the drop out rate of the CMR 
protocol was also high, but it was well comparable to those re-
ported in other important trials of the field,23 indicating that in 
general the designs of current trial protocols are challenging.
A further limitation of the study is the long recruitment pe-
riod. Finally, the biological properties of the injected BM-MNC 
may have limited the treatment effect. BM-MNC are a hetero-
genic, unselected cell population, containing only small por-
tions of cell types, which in vitro or in small-animal trials have 
been shown to exert regenerative capacity. Cell characterization 
at the time of the study enrollment was less well studied and 
was limited to the number of CD34+ and CD133+ cells (which 
were found in comparable numbers as in previous trials13). 
Nevertheless, the lack of regenerative capacity of BM-MNC in 
our trial cannot be generalized to the other selected cell types 
deriving from the bone marrow or for other progenitor cell 
types, such as selected mononuclear cells, mesenchymal stem 
cells, or cardiac stem cells. Of note, we have recently shown a 
reduced migration capacity of aged BM-MNC when compared 
with those obtained from young healthy subjects.32 Similarly, 
BM-MNC obtained from patients with diabetes mellitus or 
heart failure exhibit a reduced regenerative capacity.33 Thus, it 
is likely that BM-MNC obtained from patients of advanced age 
with LV dysfunction as in most trials may be functionally defi-
cient and hence unable to improve LVEF as has been shown in 
young rodent models without cardiovascular risk factors.
In conclusion, the Swiss-AMI trial in patients with STEMI 
and LV dysfunction intracoronary infusion of BM-MNC either 
5 to 7 days or 3 to 4 weeks after successful reperfusion therapy 
by primary PCI did not show any improvement in LVEF at 12 
months. The clinical value of BM-MNC remains unclear and, 
thus, the results of larger outcome studies, such as the ongoing 
BAMI trial (NCT 01569178), aiming to demonstrate a benefi-
cial effect of BM-MNC on 2-year survival, must be awaited.
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What Is Known?
•	 Earlier studies reported promising benefits in left ventricular remodel-
ing and function using bone marrow–derived mononuclear cell treat-
ment after acute myocardial infarction.
•	 The results of more recent trials using similar cell preparation tech-
niques are challenging the initial findings. Furthermore, the durability 
of any positive effect has not been sufficiently demonstrated.
What New Information Does This Article Contribute?
•	 The long-term results of the Swiss-AMI trial are strikingly in line with 
most recent findings in the field lacking of any positive effect on car-
diac function, remodeling, or adverse events neither 4 months nor 12 
months after myocardial infarction.
•	 Mortality, even after large myocardial infarction, is surprisingly low, 
which is gratifying for patients but may have important impacts for the 
design of future trials.
Little more than 10 years ago, bone marrow–derived progeni-
tor cells were first injected in the infarct-related artery several 
days after myocardial infarction and initial results seemed to be 
promising in terms of improvement of left ventricular function. 
The aim of the presented trial was to confirm the favorable ef-
fect on remodeling for the cell therapy groups and to address 
the ideal timing for treatment. We randomly assigned the 200 
included patients to an open-labeled control and 2 therapy arms. 
Bone marrow–derived progenitor cells were, thus, injected early 
(5–7 days) or late (3–4 weeks) after myocardial infarction. Like 
at short term, also after 12 months, we could not find any benefit 
from progenitor cell therapy on left ventricular function or major 
cardiac adverse events. Only the trends of N-terminal pro-brain 
natriuretic peptide over time may be more favorable for the cell 
therapy groups than for control groups. Overall, the mortality after 
myocardial infarction was rather low (2.25%) without significant 
difference between groups. This may have important impact on 
the design of future trials. Concluding, intracoronary infusion of 
bone marrow–derived progenitor cells either early or late after 
large acute myocardial infarction did not improve left ventricular 
function at 12 months follow-up, compared with an open-labeled, 
randomized control group.
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SUPPLEMENTAL MATERIAL 
 
Additional information concerning Methods 
  
Justification of the inclusion of baseline LVEF in models: 
 
Although the treatment arms were randomized, baseline LVEF was not completely equal in all three groups (Online Table I). Also, it has been shown in 
the past that baseline LVEF may play an important role in the interpretation of the results in studies with cell-based therapies after AMI. Especially in the 
Repair AMI trial 1, patients with a lower baseline LVEF derived the most benefit from cell therapy. Furthermore in the Regent trial 2, only for patients with 
the most depressed LVEF there was a trend in favor of cell therapy. Therefore, the conclusion has been drawn, that the difference between control and 
both therapy groups for baseline LVEF, although not completely significant when applying the Bonferroni correction, could not be ignored. Thus, 
baseline LVEF was included as covariate in all regression analyses, in order to perform adjustment for baseline LVEF. 
All other confounders collected at baseline (age, gender, history of CAD, diabetes) and included in the model were chosen both due to clinical relevance 
and some imbalance between treatment arms observed.  
 
 
Additional information concerning missingness and multiple imputation 
 
Reason for dropping out from the study is illustrated in the flowchart of Figure 1. Already for the main publication 3, we had many discussions about drop 
out rate already during review process of the primary endpoint. We concluded that drop out rate was highest in the late therapy group, where patients 
left the hospital where primary PCI was performed and had to come back for treatment (either from home or from rehabilitation unit). This incommodity 
may have led to the higher drop out rate in this group. We then tried to look at clinical parameters of those patients dropping out and compared them 
with the remaining patients. This was not easy and contained further potential bias as some patients withdrew only partial informed consent (i.e. refused 
repetitive CMR analysis) whereas others withdraw complete consent including data storage or further clinical follow-up data assessment.  
Taking into account all three study-groups, drop out patients were significantly older than those who maintained in the study (65years vs. 56 years). 
They had a trend to have higher CK max values but did not differ in terms of gender, baseline LVEF or baseline NT-proBNP.  
Looking at the same values (gender, age, baseline CK max, baseline NT-pro-BNP, baseline LVEF) as per group, we did not see a difference between 
drop-out and study-compliant patients for the control and for the late therapy group. However, drop-out patients in the early therapy group were older 
and had higher CK-max values.  
We also performed a more detailed analysis of reasons for missing data: 
We classified data not missing at random (Death, ICD implantation) and missing at random (MAR) which should be true for complete withdrawal from all 
follow-up protocols, isolated withdrawal for specific follow up protocols (no CMR for claustrophobia; refused CMR or blood sample) and for technical 
reasons (CMR not readable / interpretable; missing blood sample for oblivion). Most of the missing data were due to reasons concerning the clinical 
situation, therefore classified as MAR. Missing data classified as non-MAR, were few, i.e. death (n = 4) and ICD implantation (n = 5).  
For these reasons we performed multiple imputation using chained equation, which fills in missing values in multiple variables iteratively. The Stata 14  
mi suite was used. Fifty datasets were generated after setting a seed for reproducibility. The largest fraction of missing information (FMI) was used to 
confirm that the number of imputed data sets was adequate (thumb rule M=100*FMI). We imputed the LVEF, LVEDV, LVESV, scar size, NT-proBNP 
and their changes at 12 months.  We used the following independent variables for imputation: age, body mass index, gender, hypertension, 
dislipidemia, Diabetes, Smoking (active/previous), Familiar history of coronary artery disease, 1 / 2 / 3 vessel disease, treatment arm, time from pain to 
revascularization, TIMI flow before PCI, TIMI flow after PCI, Use of Glycoprotein IIb/IIIa inhibitors, maximal creatin kinase values, initial heart failure, 
initial ventricular fibrillation. The imputed data were then described with the mean and standard error (SE) or the median and SE obtained via quantile 
regression. The same regression models as in the complete case analysis were fitted (while accounting for imputation). 
 
 
 
Additional information for results 
 
Comparison of the two treatment arms with controls, pooled: 
Changes over time were compared between control and one pooled treatment arm (Online Figure I). The results were not different from the main 
analysis, with no significant interaction term, thus no claim of treatment effect could be made in this case either. 
 
Comparison of treatment effect after multiple imputation: 
Results of treatment comparisons after multiple imputation are shown in the Table 1B. They appear similar to the complete analysis, both in the data 
description and the comparison of time profile (p for interaction non significant in all cases); details of the regression models are reported in the Online 
Table IIIB. 
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Online figure legends 
 
Online Figure I: 
Descriptive statistic (columns) of the mean absolute change in left ventricular ejection fraction (LVEF - %), left ventricular end-diastolic volume (LVEDV - 
ml), left ventricular end-systolic volume (LVESV – ml) and NT-proBNP (pg/ml) from baseline to 12 months for control and the combined bone marrow– 
derived mononuclear cell treatment group (“early + late”). 
Online Tables 
 
Online Table I: Baseline characteristics of the included patients 
 
 
Control 
(n = 67) 
 
Early 
(n = 65) 
 
Late 
(n = 63) 
 
p-value 
Age – years (median; IQR) 56 (14.5) 55 (15) 62 (15) 0.70 * 0.06 ‡ 
BMI - kg/m2 (median; IQR) 26.7 (4.4) 27.0 (6.1) 27.0 (4.4) 0.92 * 0.89 ‡ 
Male gender - % 83.6 86.2 82.5 0.18 * 1.00 ‡ 
Hypertension - % 43.3 49.2 38.7 0.60 * 0.72 ‡ 
Hyperlipidemia - % 44.8 40.0 41.9 0.60 * 0.86 ‡ 
Diabetes  - % 17.9 7.7 9.7 0.12 * 0.21 ‡ 
Smoking (active/previous) - % 62.7 67.7 40.3 0.60 * 0.01 ‡ 
Familiar history of CAD - % 35.8 26.1 24.2 0.26 * 0.18 ‡ 
1 / 2 / 3 vessel disease % 64/21/15 54/32/14 57/27/16 0.34 * 0.73 ‡ 
Previous PCI before AMI - % 3.0 3.1 1.6 1.00 * 1.00 ‡ 
Infarct treatment   
Primary PCI – % 94.0 98.5 100.0 0.37 * 0.12 ‡ 
Concomitant PCI other 
than infarct related artery – % 18.2 12.3 11.1 
0.47 * 
0.32 ‡ 
Infarct vessel LAD/LCX/RCA -% 89/3/8 95/2/3 92/3/5 0.51 * 0.89 ‡ 
Pain to revascularization time (h) 4.5 (5) 4.8 (5.4) 4.0 (4.8) 0.57 * 0.53 ‡ 
Stent diameter (mm) 3.5 (0.5) 3.0 (0.5) 3.5 (0.5) 0.73 * 0.89 ‡ 
Drug eluting stent – % 71.6 80.0 81.0 0.31 * 0.23 ‡ 
TIMI flow before PCI 0 (0) 0 (0) 0 (0) 0.31 * 0.87 ‡ 
TIMI flow after PCI 3 (0) 3 (0) 3 (0) 0.94 * 0.81 ‡ 
Use of Glycoprotein IIb/IIIa inhibitors - % 64.2 70.8 58.7 0.27 * 0.32 ‡ 
Bivalirudin - % 7.5 7.7 19.1 0.61 * 0.04 ‡ 
Maximal creatin kinase - U/l (median; IQR) 3671 (3685) 4314 (3561) 3436 (3813) 0.22 * 0.78 ‡ 
nt-pro BNP - ng/l (median; IQR) 1103 (1848) 1450 (1442) 1581 (1912) 0.15 * 0.10 ‡ 
Intra aortic balloon pump / other assist device - % 16.4 15.6  22.6 1.00 * 0.18 ‡ 
CMR characteristics of the LV   
 LVEF – % (median;IQR) 39.6 (11.2) 
34.6 
 (16.1)  
35.6 
(11.2) 
0.07 * 
0.03 ‡ 
 LVEDV – ml (median;IQR) 154  (44) 
153  
(49) 
149  
(47)  
0.89 * 
0.96 ‡ 
 LVESV – ml (median;IQR) 94  (35) 
94  
(41) 
97  
(38)  
0.54 * 
0.41 ‡ 
Scar mass  – g (median;IQR) 39.1  (37.2) 
37.7  
(32.1) 
33.9  
(24.2)  
0.94 * 
0.21 ‡ 
Myocardial scar – % (median;IQR) 28.3 (16.3) 
28.1  
(16.2) 
26.6 
(15.9) 
0.78 * 
0.53 ‡ 
MVO – g (median;IQR) 0.27 (1.55) 
1.08 
(3.00) 
0.64 
(2.49) 
0.11 * 
0.51 ‡ 
Modified from Sürder et al. Circulation 2013 1 
IQR: interquartile range; BMI: body mass index; CAD: Coronary artery disease; PCI: Percutaneous coronary intervention; AMI: acute myocardial infarction; LAD: left anterior 
descending coronary artery; LCX: left circumflex artery; RCA right coronary artery; TIMI: Thrombolysis in Myocardial Infarction 
*: p value control vs. early 
‡: p value control vs. late 
 
 Online Table II: Characteristics of BM-MNC and cell treatment      
  Early Late 
p-value 
(between group 
difference) 
Cell characteristics   
BM aspiration volume (ml) 65 (15) 70 (15) 0.30 
Total MNC (106 cells) 159.7 (125.8) 139.5 (120.5) 0.18 
Viability - % 93.6 (5.55) 93.33 (6.60) 0.98 
% CD 34+ cells 1.02 (0.72) 1.31 (0.97) 0.01 # 
Total CD 34+ cells (106 cells) 1.6 (1.69) 1.45 (2.43) 0.68 
% CD 34+/133+ cells 0.81 (0.78) 0.87 (0.97) 0.34 
Total CD 34+/133+ cells (106 cells) 0.96 (1.46) 0.92 (2.06) 0.77 
% Invasion   33 (18) * 26.5 (16.5) ** 0.18 
Invasion index 50.88 (24.38)* 45.64 (22.10) ** 0.21 
Timing of BM-MNC treatment    
 Days after AMI  6 (2) 24 (7) NA 
Taken from Sürder et al. Circulation 2013 1 
BM: bone marrow; MNC: mononuclear cells; CD 34+ cells: mononuclear cells expressing the CD34 molecule; CD 34+/133+ cells: mononuclear cells co-expressing the CD34 
and CD133 protein; % invasion: percentage of mononuclear cells showing invasion capacity 
#: estimated Wilcoxon effect -0.31, 95% CI -0.56,-0-07); *: n = 29; **: n = 30 
 
Online Table III - Multivariable Models (p value for interaction is in bold & red) 
 
A	Complete	Case	Analysis	 	 	 	 	 	 	 B	Multiple	imputation	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
		 		 Robust	 		 		 		 		 	 		 		 Robust	 		 		 		 		
LVEF	 Coef.	 Std.	Err.	 t	 P>t	 [95%	CI]	 	 LVEF	 Coef.	 Std.	Err.	 t	 P>t	 [95%	CI]	
TREATMENT	 	 	 	 	 	 	 	 TREATMENT	 	 	 	 	 	 	
early	 -0.53	 0.33	 -1.571	 0.118	 -1.19	 0.13	 	 early	 -0.47	 0.60	 -0.790	 0.432	 -1.65	 0.71	
late	 -0.62	 0.37	 -1.691	 0.093	 -1.34	 0.10	 	 late	 -0.51	 0.64	 -0.796	 0.428	 -1.78	 0.76	
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
MONTHS	 	 	 	 	 	 	 	 MONTHS	 	 	 	 	 	 	
4	 -0.53	 1.15	 -0.465	 0.642	 -2.79	 1.73	 	 4	 -0.54	 1.19	 -0.450	 0.653	 -2.89	 1.82	
12	 -1.89	 1.36	 -1.390	 0.166	 -4.56	 0.79	 	 12	 -1.43	 1.30	 -1.098	 0.274	 -4.00	 1.14	
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
TREATMENT#MONTHS	 	 	 0.640	 	 	 	 TREATMENT#MONTHS	 	 	 0.688	 	 	
early#	4	 2.28	 1.60	 1.426	 0.156	 -0.87	 5.42	 	 early#	4	 2.07	 1.65	 1.251	 0.213	 -1.20	 5.34	
early#12	 1.10	 1.99	 0.552	 0.582	 -2.83	 5.04	 	 early#12	 0.83	 1.89	 0.439	 0.661	 -2.90	 4.55	
late#	4	 1.40	 1.59	 0.885	 0.377	 -1.73	 4.53	 	 late#	4	 1.27	 1.66	 0.766	 0.445	 -2.00	 4.54	
late#12	 1.23	 2.08	 0.592	 0.555	 -2.88	 5.35	 	 late#12	 1.51	 1.90	 0.795	 0.428	 -2.25	 5.28	
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
LVEFbaseline	 0.86	 0.04	 20.892	 0.000	 0.78	 0.94	 	 LVEFbaseline	 0.86	 0.04	 21.255	 0.000	 0.78	 0.94	
age	 -0.01	 0.04	 -0.189	 0.850	 -0.08	 0.07	 	 age	 -0.01	 0.04	 -0.187	 0.852	 -0.08	 0.07	
gender	 1.54	 1.38	 1.112	 0.268	 -1.19	 4.26	 	 gender	 1.31	 1.29	 1.012	 0.313	 -1.25	 3.86	
DM	 -0.18	 1.17	 -0.155	 0.877	 -2.49	 2.13	 	 DM	 0.35	 1.17	 0.295	 0.768	 -1.97	 2.66	
CAD	 0.04	 0.59	 0.073	 0.942	 -1.12	 1.21	 	 CAD	 -0.10	 0.57	 -0.171	 0.864	 -1.22	 1.03	
_cons	 4.33	 2.82	 1.537	 0.126	 -1.23	 9.89	 	 _cons	 4.46	 2.95	 1.509	 0.134	 -1.38	 10.30	
Model	 F	(13,	174)	 61.11	 p<0.001	 R-squared	 0.56	 	 	 Model	 F	(13,	183)		 42.02	 p<0.001	 	 	 	
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
		 		 Robust	 		 		 		 		 	 		 		 Robust	 		 		 		 		
LVEDV	 Coef.	 Std.	Err.	 t	 P>t	 [95%	CI]	 	 LVEDV	 Coef.	 Std.	Err.	 t	 P>t	 [95%	CI]	
TREATMENT	 	 	 	 	 	 	 	 TREATMENT	 	 	 	 	 	 	
early	 -2.13	 6.67	 -0.319	 0.750	 -15.30	 11.05	 	 early	 -3.25	 6.85	 -0.474	 0.636	 -16.77	 10.28	
late	 2.31	 6.18	 0.373	 0.709	 -9.89	 14.50	 	 late	 0.85	 6.55	 0.130	 0.897	 -12.10	 13.80	
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
MONTHS	 	 	 	 	 	 	 	 MONTHS	 	 	 	 	 	 	
4	 27.88	 5.04	 5.528	 0.000	 17.92	 37.83	 	 4	 25.67	 5.71	 4.496	 0.000	 14.38	 36.95	
12	 18.04	 7.14	 2.528	 0.012	 3.95	 32.13	 	 12	 16.56	 7.16	 2.312	 0.022	 2.41	 30.72	
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
TREATMENT#MONTHS	 	 	 0.063	 	 	 	 TREATMENT#MONTHS	 	 	 0.292	 	 	
early#	4	 -0.61	 6.52	 -0.093	 0.926	 -13.47	 12.25	 	 early#	4	 -1.12	 7.58	 -0.148	 0.883	 -16.11	 13.87	
early#12	 6.84	 9.43	 0.725	 0.470	 -11.78	 25.45	 	 early#12	 4.27	 9.81	 0.435	 0.664	 -15.11	 23.65	
late#	4	 -17.92	 7.34	 -2.442	 0.016	 -32.41	 -3.44	 	 late#	4	 -16.40	 8.39	 -1.956	 0.053	 -32.99	 0.19	
late#12	 -8.55	 9.69	 -0.882	 0.379	 -27.68	 10.58	 	 late#12	 -10.22	 10.32	 -0.990	 0.324	 -30.64	 10.20	
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
LVEFbaseline	 -1.84	 0.28	 -6.631	 0.000	 -2.38	 -1.29	 	 LVEFbaseline	 -1.84	 0.26	 -7.199	 0.000	 -2.34	 -1.33	
age	 -0.71	 0.25	 -2.801	 0.006	 -1.20	 -0.21	 	 age	 -0.78	 0.25	 -3.089	 0.002	 -1.28	 -0.28	
gender	 -27.29	 7.64	 -3.572	 0.000	 -42.37	 -12.21	 	 gender	 -26.26	 7.30	 -3.596	 0.000	 -40.69	 -11.83	
DM	 9.12	 13.34	 0.684	 0.495	 -17.20	 35.45	 	 DM	 6.36	 11.43	 0.557	 0.578	 -16.20	 28.93	
CAD	 -0.82	 4.44	 -0.186	 0.853	 -9.58	 7.93	 	 CAD	 -0.27	 4.13	 -0.064	 0.949	 -8.42	 7.89	
_cons	 296.16	 20.17	 14.683	 0.000	 256.35	 335.97	 	 _cons	 300.73	 19.97	 15.063	 0.000	 261.29	 340.17	
Model	 F	(13,	174)	 10.75	 p<0.001	 R-squared	 0.25	 	 	 Model	 F	(13,	183)	 8.29	 p<0.001	 	 	 	
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
		 		 Robust	 		 		 		 		 	 		 		 Robust	 		 		 		 		
LVESV	 Coef.	 Std.	Err.	 t	 P>t	 [95%	CI]	 	 LVESV	 Coef.	 Std.	Err.	 t	 P>t	 [95%	CI]	
TREATMENT	 	 	 	 	 	 	 	 TREATMENT	 	 	 	 	 	 	
early	 -2.12	 4.44	 -0.478	 0.633	 -10.89	 6.64	 	 early	 -2.67	 4.75	 -0.562	 0.575	 -12.05	 6.71	
late	 0.28	 4.03	 0.069	 0.945	 -7.68	 8.23	 	 late	 -0.86	 4.59	 -0.187	 0.852	 -9.92	 8.21	
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
MONTHS	 	 	 	 	 	 	 	 MONTHS	 	 	 	 	 	 	
4	 19.34	 4.23	 4.570	 0.000	 10.98	 27.69	 	 4	 17.86	 4.78	 3.738	 0.000	 8.41	 27.30	
12	 16.83	 6.06	 2.778	 0.006	 4.87	 28.79	 	 12	 15.02	 5.97	 2.518	 0.013	 3.23	 26.80	
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
TREATMENT#MONTHS	 	 	 0.199	 	 	 	 TREATMENT#MONTHS	 	 	 0.490	 	 	
early#	4	 -2.74	 5.78	 -0.474	 0.636	 -14.15	 8.67	 	 early#	4	 -3.05	 6.57	 -0.464	 0.643	 -16.04	 9.94	
early#12	 3.24	 8.34	 0.389	 0.698	 -13.22	 19.71	 	 early#12	 1.79	 8.33	 0.215	 0.830	 -14.67	 18.26	
late#	4	 -12.97	 6.18	 -2.099	 0.037	 -25.17	 -0.78	 	 late#	4	 -11.87	 7.03	 -1.690	 0.093	 -25.77	 2.03	
late#12	 -7.66	 8.24	 -0.929	 0.354	 -23.93	 8.61	 	 late#12	 -9.08	 8.59	 -1.057	 0.292	 -26.06	 7.91	
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
LVEFbaseline	 -2.55	 0.22	 -11.645	 0.000	 -2.99	 -2.12	 	 LVEFbaseline	 -2.56	 0.20	 -12.634	 0.000	 -2.96	 -2.16	
age	 -0.45	 0.20	 -2.199	 0.029	 -0.85	 -0.05	 	 age	 -0.50	 0.21	 -2.428	 0.016	 -0.92	 -0.09	
gender	 -18.33	 6.60	 -2.776	 0.006	 -31.37	 -5.30	 	 gender	 -17.34	 6.27	 -2.766	 0.006	 -29.73	 -4.95	
DM	 4.66	 10.35	 0.450	 0.653	 -15.77	 25.09	 	 DM	 1.99	 8.93	 0.222	 0.824	 -15.65	 19.62	
CAD	 -0.19	 3.65	 -0.051	 0.959	 -7.39	 7.01	 	 CAD	 0.47	 3.41	 0.139	 0.890	 -6.25	 7.19	
_cons	 241.07	 16.04	 15.028	 0.000	 209.41	 272.73	 	 _cons	 244.37	 16.09	 15.191	 0.000	 212.59	 276.15	
Model	 F	(13,	174)	 15.19	 p<0.001	 R-squared	 0.36	 	 	 Model	 F	(13,	183)	 14.13	 p<0.001	 	 	 	
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
		 		 Robust	 		 		 		 		 	 		 		 Robust	 		 		 		 		
Infarct	size	(g)	 Coef.	 Std.	Err.	 t	 P>t	 [95%	CI]	 	 Infarct	size	(g)	 Coef.	 Std.	Err.	 t	 P>t	 [95%	CI]	
TREATMENT	 	 	 	 	 	 	 	 TREATMENT	 	 	 	 	 	 	
early	 -3.86	 4.36	 -0.884	 0.378	 -12.47	 4.76	 	 early	 -2.01	 4.35	 -0.462	 0.645	 -10.60	 6.58	
late	 -9.18	 4.42	 -2.079	 0.039	 -17.90	 -0.47	 	 late	 -8.42	 4.23	 -1.989	 0.048	 -16.77	 -0.07	
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
MONTHS	 	 	 	 	 	 	 	 MONTHS	 	 	 	 	 	 	
4	 -16.39	 2.97	 -5.522	 0.000	 -22.25	 -10.53	 	 4	 -14.69	 3.00	 -4.900	 0.000	 -20.61	 -8.76	
12	 -23.91	 3.49	 -6.846	 0.000	 -30.81	 -17.02	 	 12	 -20.74	 3.28	 -6.331	 0.000	 -27.21	 -14.27	
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
TREATMENT#MONTHS	 	 	 0.181	 	 	 	 TREATMENT#MONTHS	 	 	 0.702	 	 	
early#	4	 0.74	 3.88	 0.192	 0.848	 -6.92	 8.40	 	 early#	4	 -0.40	 4.12	 -0.098	 0.922	 -8.54	 7.73	
early#12	 4.65	 4.39	 1.058	 0.291	 -4.02	 13.32	 	 early#12	 1.88	 4.47	 0.420	 0.675	 -6.96	 10.71	
late#	4	 2.34	 4.24	 0.551	 0.582	 -6.02	 10.69	 	 late#	4	 1.89	 4.27	 0.442	 0.659	 -6.55	 10.33	
late#12	 8.70	 5.03	 1.730	 0.085	 -1.22	 18.62	 	 late#12	 6.00	 4.75	 1.262	 0.209	 -3.39	 15.39	
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
LVEFbaseline	 -0.83	 0.10	 -8.404	 0.000	 -1.02	 -0.63	 	 LVEFbaseline	 -0.86	 0.10	 -8.307	 0.000	 -1.06	 -0.65	
age	 0.10	 0.09	 1.141	 0.255	 -0.07	 0.28	 	 age	 0.11	 0.10	 1.106	 0.270	 -0.09	 0.30	
gender	 -8.96	 2.25	 -3.981	 0.000	 -13.40	 -4.52	 	 gender	 -8.78	 2.62	 -3.347	 0.001	 -13.97	 -3.58	
DM	 1.46	 2.70	 0.541	 0.589	 -3.86	 6.78	 	 DM	 1.25	 2.85	 0.440	 0.661	 -4.37	 6.88	
CAD	 -1.83	 1.18	 -1.556	 0.122	 -4.16	 0.49	 	 CAD	 -1.72	 1.29	 -1.333	 0.185	 -4.26	 0.83	
_cons	 85.35	 8.16	 10.458	 0.000	 69.24	 101.46	 	 _cons	 84.45	 9.01	 9.370	 0.000	 66.65	 102.25	
Model	 F	(13,	174)	 16.50	 p<0.001	 R-squared	 0.36	 	 	 Model	 F	(13,	183)	 13.20	 p<0.001	 	 	 	
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
		 		 Robust	 		 		 		 		 	 		 		 Robust	 		 		 		 		
ln-proBNP	 Coef.	 Std.	Err.	 t	 P>t	 [95%	CI]	 	 ln-proBNP	 Coef.	 Std.	Err.	 t	 P>t	 [95%	CI]	
TREATMENT	 	 	 	 	 	 	 	 TREATMENT	 	 	 	 	 	 	
early	 0.13	 0.15	 0.831	 0.407	 -0.17	 0.42	 	 early	 0.20	 0.15	 1.336	 0.183	 -0.10	 0.50	
late	 0.11	 0.17	 0.674	 0.501	 -0.22	 0.44	 	 late	 0.06	 0.17	 0.331	 0.741	 -0.28	 0.39	
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
MONTHS	 	 	 	 	 	 	 	 MONTHS	 	 	 	 	 	 	
4	 -1.01	 0.14	 -7.123	 0.000	 -1.29	 -0.73	 	 4	 -0.89	 0.14	 -6.207	 0.000	 -1.17	 -0.61	
12	 -1.32	 0.18	 -7.470	 0.000	 -1.66	 -0.97	 	 12	 -1.19	 0.17	 -6.959	 0.000	 -1.53	 -0.86	
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
TREATMENT#MONTHS	 	 	 0.404	 	 	 	 TREATMENT#MONTHS	 	 	 0.736	 	 	
early#	4	 -0.14	 0.17	 -0.858	 0.392	 -0.48	 0.19	 	 early#	4	 -0.23	 0.18	 -1.244	 0.215	 -0.59	 0.13	
early#12	 -0.25	 0.20	 -1.219	 0.225	 -0.65	 0.15	 	 early#12	 -0.31	 0.21	 -1.472	 0.143	 -0.73	 0.11	
late#	4	 -0.12	 0.19	 -0.607	 0.544	 -0.50	 0.26	 	 late#	4	 -0.12	 0.21	 -0.561	 0.576	 -0.54	 0.30	
late#12	 -0.33	 0.23	 -1.460	 0.146	 -0.78	 0.12	 	 late#12	 -0.23	 0.24	 -0.962	 0.337	 -0.71	 0.25	
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
LVEFbaseline	 -0.04	 0.00	 -7.760	 0.000	 -0.05	 -0.03	 	 LVEFbaseline	 -0.04	 0.01	 -7.965	 0.000	 -0.05	 -0.03	
age	 0.03	 0.00	 5.584	 0.000	 0.02	 0.04	 	 age	 0.03	 0.00	 5.759	 0.000	 0.02	 0.04	
gender	 0.31	 0.14	 2.163	 0.032	 0.03	 0.59	 	 gender	 0.29	 0.14	 2.041	 0.043	 0.01	 0.57	
DM	 0.02	 0.17	 0.108	 0.914	 -0.33	 0.36	 	 DM	 -0.02	 0.17	 -0.090	 0.929	 -0.35	 0.32	
CAD	 -0.05	 0.08	 -0.604	 0.547	 -0.20	 0.11	 	 CAD	 -0.04	 0.07	 -0.542	 0.589	 -0.19	 0.11	
_cons	 6.78	 0.41	 16.656	 0.000	 5.98	 7.59	 	 _cons	 6.71	 0.42	 15.884	 0.000	 5.87	 7.54	
Model	 F	(13,	172)	 52.89	 p<0.001	 R-squared	 0.49	 	 	 Model	 F	(13,	183)	 34.61	 p<0.001	 	 	 	
 
Online Table III reports the entire statistical results obtained with STATA: Modeling of LVEF, LVEDV, LVESV, MI mass and ln-proBNP (log-transformed NT-
proBNP) as dependent variables and treatment (TREATMENT), months of follow-up (MONTHS) and their interaction (TREATMENT#MONTHS) as 
independent variables. The purpose of the model is to verify whether profiles over time differ between treatment arms by testing this interaction. The p-value for 
interaction is reported in red and bold in the TREATMENT#MONTHS line. 
Coef.: Regression coefficient; Robust Std. Err.: Huber-White robust standard error; t: t statistic to that tests whether coefficients are = 0; P>t: Corresponding p-
value; [95% Conf. Interval]: 95% confidence interval of the regression coefficient. 
Model F statistic and p-value, together with the model explained variation (R squared) are reported below each model report.  
Both the analysis on raw data (A) and the analysis on multiple imputation (B) are shown.  
 
 
 
Online Figure I: 
 
 
 
